Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Veritas In Silico Inc. ( (JP:130A) ).
Veritas In Silico Inc. has released its financial results for the third quarter of the fiscal year ending December 2025. The announcement highlights the company’s ongoing efforts and strategic positioning in the mRNA-targeted drug market, which could have significant implications for its stakeholders and the broader pharmaceutical industry.
More about Veritas In Silico Inc.
Veritas In Silico Inc. operates in the pharmaceutical industry, focusing on the development of mRNA-targeted drugs. The company is dedicated to bringing new hope through its innovative drug solutions, aiming to impact the healthcare market significantly.
Average Trading Volume: 56,438
Technical Sentiment Signal: Sell
Current Market Cap: Yen3.57B
For an in-depth examination of 130A stock, go to TipRanks’ Overview page.